Vanda Pharmaceuticals Inc.
VNDA
$3.83
-$0.095-2.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -805.05% | -853.29% | -239.24% | -173.32% | -130.64% |
| Total Depreciation and Amortization | 72.90% | 170.17% | 190.93% | 126.94% | 68.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -199.26% | -80.46% | -125.00% | -89.71% | -63.61% |
| Change in Net Operating Assets | 2.27% | -777.91% | 9.36% | -117.28% | -156.13% |
| Cash from Operations | -393.95% | -223.09% | -168.10% | -112.59% | -119.14% |
| Capital Expenditure | 97.64% | 95.33% | -26,725.19% | -20,264.80% | -15,733.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 141.40% | -114.28% | -62.61% | 25.28% | -150.16% |
| Cash from Investing | 120.54% | -44.58% | -160.85% | -183.79% | -196.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -733.33% | -446.81% | 136.25% | -100.38% | -103.27% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.17% | -4,330.43% | -161.81% | -151.31% | -179.74% |